Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Post-Market Trading 11-25 17:15:59 EST

1.31

-0.01

-0.76%

盘后1.32

+0.01+0.76%

17:10 EST

High1.43	Low1.27	Vol561.96K
Open1.35	D1 Closing1.32	Amplitude11.73%
Mkt Cap21.69M	Tradable Cap14.36M	Total Shares16.56M
T/O749.42K	T/O Rate5.13%	Tradable Shares10.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.31,"timestamp":1732568400000,"preClose":1.32,"halted":0,"volume":561955,"hourTrading":{"tag":"盘后","latestPrice":1.3199,"preClose":1.31,"latestTime":"17:10 EST","volume":2264,"amount":2986.3310112000004,"timestamp":1732572630101},"delay":0,"floatShares":10962400,"shares":16560852,"eps":-0.572298,"marketStatus":"Post-Market Trading","change":-0.01,"latestTime":"11-25 17:15:59 EST","open":1.35,"high":1.425,"low":1.2701,"amount":749420.2096385,"amplitude":0.117348,"askPrice":1.32,"askSize":2700,"bidPrice":1.29,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.572298,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732582800000},"marketStatusCode":4,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.32,"preHourTrading":{"tag":"盘前","latestPrice":1.33,"preClose":1.32,"latestTime":"09:20 EST","volume":4971,"amount":6858.1660821,"timestamp":1732544421543},"postHourTrading":{"tag":"盘后","latestPrice":1.3199,"preClose":1.31,"latestTime":"17:10 EST","volume":2264,"amount":2986.3310112000004,"timestamp":1732572630101},"volumeRatio":1.071795},"requestUrl":"/m/hq/s/MIRA/tweets","defaultTab":"tweets","newsList":[{"id":"2485426470","title":"MIRA Pharmaceuticals Appoints New Board Member and Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2485426470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485426470?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:48","pubTimestamp":1732225696,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an update. MIRA Pharmaceuticals, Inc. announces a significant leadership change as Michael Jerman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-board-member-and-chairman?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-board-member-and-chairman?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2484011565","title":"MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2484011565","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484011565?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:44","pubTimestamp":1732106640,"startTime":"0","endTime":"0","summary":"Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment. MIAMI, FL / ACCESSWIRE / November 20, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company, is pleased to announce the selection of The Centre for Human Drug Research  in Leiden, The Netherlands, as the site for its Phase I/IIa clinical trial of Ketamir-2, a novel oral ketamine analog. Recruitment for the trial is set to begin in Q1 2025, with initial safety and efficacy results from the Phase I study in healthy subjects expected in the second half of 2025. The Phase IIa study, planned to start in Q4 2025, will focus on diabetic neuropathy patients, with initial human efficacy results anticipated in the first half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-reveals-innovative-phase-iia-124400230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2483832346","title":"MIRA Continues Solid Financial Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2483832346","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483832346?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just released further study results that, in our view, boost the potential for the treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-continues-solid-financial-management-110000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2479282498","title":"MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2479282498","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479282498?lang=en_us&edition=fundamental","pubTime":"2024-10-29 22:57","pubTimestamp":1730213864,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  shares soared by 40% after the company achieved a significant breakthrough in chemotherapy pain management with its new drug, Ketamir-2. According to recent studies, Ketamir-2 is proven to be 2% more effective than existing FDA-approved medications, specifically Gabapentin and Pregabalin, in alleviating chemotherapy-induced neuropathic pain. Preclinical studies have highlighted Ketamir-2's superior performance, demonstrating a 60% higher efficacy compared to Gabapentin and a remarkable 112% improvement over Pregabalin in various neuropathic models.GuruFocus has detected 4 Warning Signs with TMDX.In addition to ketamine-2, MIRA Pharmaceuticals is also active in developing MIRA-55, an oral agent with a similar mechanism as ketamine-2 used in the treatment of anxiety and cognitive symptoms in early dementia. With Ketamir-2 moving towards clinical trial and possibly receiving expedited approval by the FDA, it becomes a true light at the end of the tunnel for those suf","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BWrQl6JsGtld4ws6on8CBg--~B/aD0zNjY7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/6b4169c961bedd8366201c4b184072f0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BWrQl6JsGtld4ws6on8CBg--~B/aD0zNjY7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/6b4169c961bedd8366201c4b184072f0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-shares-surge-40-145744961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2479437743","title":"MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479437743","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479437743?lang=en_us&edition=fundamental","pubTime":"2024-10-29 01:40","pubTimestamp":1730137258,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc.  stock is trading higher on Monday after the company released new preclinical findings from Ketamir-2, a novel oral ketamine analog.The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain.Also Read: MIRA Pharmaceuticals’ Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies. On Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provided only moderate relief.To maximize the development timeline, MIRA is considering conducting multiple Phase 2 trials in parallel, specifically targeting neuropathic pain across different patient populations, which could further accelerate Ketamir-2’s path to market.In addition to the ongoing studies, MIRA is in the process of submitting several scientific journal publications that","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/92kmnbogljGXGlbq7JI58A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/504361aa1cf5cd6d696519cc9da86e9f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/92kmnbogljGXGlbq7JI58A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/504361aa1cf5cd6d696519cc9da86e9f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-formulated-shows-greater-174058339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","SAVAW","SAVA","BK4007","VFF","BK4189"],"gpt_icon":0},{"id":"2478101693","title":"Mira Pharmaceuticals announces preclinical data on Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2478101693","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478101693?lang=en_us&edition=fundamental","pubTime":"2024-10-28 19:45","pubTimestamp":1730115932,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announces new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, achieves 60% greater efficacy ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-preclinical-data-on-ketamir-2-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-preclinical-data-on-ketamir-2-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2478942104","title":"MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2478942104","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478942104?lang=en_us&edition=fundamental","pubTime":"2024-10-28 19:30","pubTimestamp":1730115000,"startTime":"0","endTime":"0","summary":"Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at the Pain Therapeutics Summit in Boston. MIAMI, FL / ACCESSWIRE / October 28, 2024 / MIRA Pharmaceuticals, Inc. , a leading pre-clinical-stage pharmaceutical development company, announces compelling new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, achieves 60% greater efficacy than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain. These results build on earlier successes across various pain models, further validating Ketamir-2's potential to set a new standard in pain management.The study used the paclitaxel  model, where neuropathic pain was induced in mice through the administration of PTX, a common chemotherapy drug. While effective in treating cancer, PTX often causes nerve damage, leading to chemotherapy-induced neuropathy characterized by pain, numbness, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-ketamir-2-shows-113000711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4189","VFF","MIRA"],"gpt_icon":1},{"id":"2478191065","title":"Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478191065","media":"Market Exclusive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478191065?lang=en_us&edition=fundamental","pubTime":"2024-10-28 05:34","pubTimestamp":1730064844,"startTime":"0","endTime":"0","summary":"Chicago Atlantic REIT secured a $50 million loan to fund new marijuana investments. Canopy Growth reduced loan term by $100 million to strengthen financial position. RIV Capital reported doubling revenue, and strong synergy gains ahead of Cansortium merger. Awakn expanded phase 3 trial sites for alcohol use disorder. MIRA Pharmaceuticals announced breakthrough with ketamine-based pain treatment. Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.Canopy Growth Corporation  , a leading Canadian cannabis operator, made a strategic move to improve its financial standing by reducing a loan term by $100 million . This prepayment allowed the company to decrease its debt at a disco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-213404393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REFI","BK4104","BK4110","BK4125","CGC","MIRA","BK4007","BK4557","AUD","MRC"],"gpt_icon":1},{"id":"2477594508","title":"MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2477594508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477594508?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:50","pubTimestamp":1729511406,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-says-ketamir-2-outperforms-fda-approved-neuropathic-pain-treatments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-says-ketamir-2-outperforms-fda-approved-neuropathic-pain-treatments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA"],"gpt_icon":0},{"id":"2477859988","title":"MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2477859988","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477859988?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:30","pubTimestamp":1729510200,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. , a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments Gabapentin  and Pregabalin . Ketamir-2, a non-opioid, offers tremendous promise for patients seeking better solutions for neuropathic pain without the habit-forming risks or debilitating side effects associated with existing medications.The latest preclinical study, conducted using a nerve ligation-induced neuropathy model in female rats, demonstrated that low doses of oral Ketamir-2 provided significant pain relief by Day 15. By Day 22, Ketamir-2 achieved up to 112% more effective results than Pregabalin and 70% greater relief than Gabapentin at higher doses. These findings build on prior studies in male rats, where Ketamir-2 fully reversed neuropathic pain, while oral ketamine showed no effect. This consistent eff","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-announces-ketamir-2-113000149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA"],"gpt_icon":0},{"id":"2477853155","title":"Mira Pharmaceuticals Inc - Reports Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2477853155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477853155?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:02","pubTimestamp":1729508533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nFWN3LX0K2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2477853116","title":"Mira Pharmaceuticals - Remains on Track to Submit Ind Application by End of 2024, With Phase I Clinical Trials Expected to Begin in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2477853116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477853116?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:02","pubTimestamp":1729508533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nFWN3LX0K2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2477861328","title":"MIRA Continues to Post Outstanding Test Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2477861328","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477861328?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:20","pubTimestamp":1729506000,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just released further study results that, in our view, boost the potential for the treatment.As a result of these announcements, which we believe increases the odds of approval and commercialization and potentially expands the patient p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-continues-post-outstanding-test-102000323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4212","POST","MIRA"],"gpt_icon":0},{"id":"2471838529","title":"Mira Pharmaceuticals initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2471838529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471838529?lang=en_us&edition=fundamental","pubTime":"2024-09-30 21:40","pubTimestamp":1727703637,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw analyst Elemer Piros initiated coverage of Mira Pharmaceuticals with a Buy rating and $17 price target. Mira is developing next-ge...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2470068208","title":"BRIEF-Mira Pharmaceuticals May Offer,Sell Shares Of Common Stock Of Up To $75 Million From Time To Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2470068208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470068208?lang=en_us&edition=fundamental","pubTime":"2024-09-28 06:02","pubTimestamp":1727474566,"startTime":"0","endTime":"0","summary":"Sept 27 (Reuters) - Mira Pharmaceuticals Inc   :   * MIRA PHARMACEUTICALS - MAY OFFER,SELL SHARES OF COMMON STOCK OF UP TO $75 MILLION FROM TIME TO TIMESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2470707220","title":"MIRA Pharma Says Ketamir-2 Achieved 100% Neuropathic Pain Reversal in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2470707220","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470707220?lang=en_us&edition=fundamental","pubTime":"2024-09-27 20:26","pubTimestamp":1727439976,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  said Friday that preclinical data showed its oral ketamine analog Ketamir-2 achieved a \"complete reversal of neuropathic pain in preclinical models.\"In preclinical studies, Ketamir-2 showed \"superior efficacy\" compared with ketamine, the company said, adding that it is on track to submit an investigational new drug application to the US Food and Drug Administration by December.MIRA Pharmaceuticals said it plans to show an efficacy signal in humans in 2025.Shares of the company were up 2.8% in recent premarket activity.Price: 1.1000, Change: +0.03, Percent Change: +2.80","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2470704924","title":"MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2470704924","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470704924?lang=en_us&edition=fundamental","pubTime":"2024-09-27 19:30","pubTimestamp":1727436600,"startTime":"0","endTime":"0","summary":"Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic pain. The Summit is a leading forum for researchers, clinicians, and industry experts to discuss innovative solutions in pain management. MIRA Pharmaceuticals' participation highlights its commitment to addressing critical unmet medical needs in neuropathic pain, a chronic and debilitating condition with limited treatment options.MIRA is advancing the development of Ketamir-2 through ongoing preclinical studies and is preparing to publish its findings in peer-reviewed journals. The company remains on track to submit an Investigational New Drug  application to the U.S. FDA by December 2024, with plans to demonstrate an efficacy signal in humans as early as 2025. To achieve this, MIRA has designed strategic Phase I/II studies aimed at showcasing Ketamir-2's clinical effectivene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-announces-preclinical-data-113000705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","SMMF","LENZ","BK4139","BK4211","BK4007"],"gpt_icon":0},{"id":"2468525559","title":"MIRA Makes Impressive Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2468525559","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468525559?lang=en_us&edition=fundamental","pubTime":"2024-09-18 23:18","pubTimestamp":1726672680,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just released further study results that, in our view, boost the potential for the treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-makes-impressive-progress-151800872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","MIRA","BK4097","PRGS","BK4007"],"gpt_icon":1},{"id":"2468930479","title":"Mira Pharmaceuticals: Advances Ketamir-2 Development, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2468930479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468930479?lang=en_us&edition=fundamental","pubTime":"2024-09-18 19:07","pubTimestamp":1726657622,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nFWN3KZ1AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2468302200","title":"MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2468302200","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468302200?lang=en_us&edition=fundamental","pubTime":"2024-09-18 19:00","pubTimestamp":1726657200,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESSWIRE / September 18, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neuropsychiatric disorders, today announced significant progress in the clinical development planning for its novel oral ketamine analog. As part of its strategic development plan, MIRA is prioritizing the early demonstration of clinical efficacy, potentially as early as 2025, through innovative Phase I/II study designs.Drug Product Development InitiatedMIRA has initiated drug product development  of its novel oral ketamine analog in collaboration with Formulex, a leader in nano-technology-based drug delivery and formulation. This partnership focuses on spray-dry based granulation of Ketamir-2 in capsules for clinical studies, optimizing the formulation for improved oral bioavailability and patient convenience.Phase I Clinical Development Plan FinalizedMIRA has completed the design of its Phase I clinical tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-advances-ketamir-2-110000989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","GLP","BK4007","BK4590","MIRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":-0.1429},{"period":"1month","weight":0.2336},{"period":"3month","weight":-0.2865},{"period":"6month","weight":0.4915},{"period":"1year","weight":-0.5869},{"period":"ytd","weight":0.2571}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}